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A New Player on the Psoriasis Block:
IL-17A- and IL-22-Producing Innate
Lymphoid Cells
Nicole L. Ward1 and Dale T. Umetsu2
Innate lymphoid cells (ILCs) are a recently discovered family of innate immune
cells belonging to the lymphoid lineage, yet lacking antigen-specific receptors.
ILCs were first identified in the intestinal tract, where they contribute to epithelial
barrier integrity and host responses to commensal microbes. Teunissen et al. (in
the current issue) and Villanova et al. (2014) now suggest an important role for
type 3 ILCs (ILC3s) in the skin, particularly in psoriasis. Both groups found an
increased frequency of IL-22- and/or IL-17A-producing ILCs in psoriatic skin and
blood. These cells are activated in response to IL-1b and IL-23, correlate with
disease severity, and are decreased following antitumor necrosis factor-a (anti-
TNFa) treatment. The presence of a novel ILC population in psoriatic skin, one
that responds to biologic therapeutics, suggests that dysregulation of ILCs is a
contributing factor to psoriasis pathogenesis.
Journal of Investigative Dermatology (2014) 134, 2305–2307. doi:10.1038/jid.2014.216
Innate lymphoid cells (ILCs) represent a
family of multifunctional, lymphoid-
lineage cells that lack B- and T-cell
receptors and display innate immune
effector functions. These cells often
reside at mucosal interfaces where they
rapidly produce cytokines in response to
environmental challenges. At least three
groups of ILCs have been identified,
based upon unique transcription factor
utilization, cytokine profiles, and effec-
tor functions. Groups 1 and 2 produce
type 1 and 2 cytokines, respectively,
whereas group 3 has a unique capacity
to produce IL-17A and IL-22. Dysregu-
lation of ILCs has been implicated in
autoimmune and inflammatory diseases,
thus broadening our understanding of
how innate immune cells contribute to
disease pathogenesis.
However, less well understood
until now is the potential role of ILCs
in psoriasis. Two papers, both published
in the Journal of Investigative Dermato-
logy in 2014 (Teunissen et al., 2014;
Villanova et al., 2014), provide com-
pelling evidence for a pathogenic role of
ILCs in psoriasis. Teunissen et al. (2014)
show the upregulation of group 3 ILCs
(ILC3s) in nonlesional and lesional
skin and in blood of psoriasis patients,
and that these cells are novel cellular
sources of IL-22 in the skin. Nestle
and colleagues (Villanova et al., 2014)
demonstrate a close association bet-
ween disease improvement and the
number of IL-17A- and IL-22-producing
ILC3s in the skin and in circulation
following antitumor necrosis factor-a
(anti-TNFa) therapy, suggesting that
ILC3s contribute to the pathogenesis of
psoriasis.
ILCs
ILCs lack T-cell receptors and B-cell
receptors, and therefore are antigen non-
specific; however, they respond rapidly
to environmental challenges, such as
tissue injury or infection, via cytokine
secretion. Type 1 ILCs, or ILC1s, require
the transcription factor T-bet, are
induced in response to IL-12, produce
type 1 cytokines such as IFNg, and have
been observed in the intestines of
patients with inflammatory bowel dis-
ease. Type 2 ILCs, or ILC2s, require the
transcription factor RORa and GATA3,
respond to the innate cytokines IL-33, IL-
25, and thymic stromal lymphopoietin
(TSLP), produce IL-5 and IL-13 but not
IL-4, and have been found in the intes-
tines in the context of helminth infection
(Neill et al., 2010), in the lungs in the
context of asthma (Chang et al., 2011),
and in the skin in the context of atopic
dermatitis (Salimi et al., 2013). Type 3
ILCs, or ILC3s, require the transcription
factor RORgt, respond to IL-23 and IL-
1b, and produce IL-17A and/or IL-22.
ILC3s producing IL-17A have been
observed in the intestines of patients
with Crohn’s disease (Coccia et al.,
2012) and in the lungs of patients with
nonallergic asthma (Kim et al., 2014).
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ILCs and skin inflammation
A role for ILC3s in human skin has until
now remained unexplained. In murine
studies, psoriasiform skin inflammation
was still observed in Aldara-treated
Rag2 / mice, despite the lack of lym-
phocytes and natural killer T cells
(Hedrick et al., 2009; Pantelyushin
et al., 2012). Sustained expression of IL-
17A and IL-22 in the skin of these mice
suggested an alternative innate cellular
source for these psoriasis-critical
cytokines. Indeed, Pantelyushin et al.
(2012) demonstrated the presence of IL-
22-producing ILC3s in Aldara-induced
skin inflammation that mediated the
inflammatory response to Aldara,
because backcrossing the Rag2 /
mice with IL2rgc / mice, which lack
ILCs, eliminated the response to Aldara.
The work of Teunissen et al. (2014) in
this issue, along with that recently
published by Villanova et al. (2014),
translates these findings into human
skin disease and provides new insights
into the role of ILC3s in psoriasis.
These studies identify a
novel ILC population in
psoriatic skin that
responds to biologic
therapeutics, thus
suggesting that
dysregulation of ILCs is a
contributing factor to
psoriasis pathogenesis.
Clinical context of ILCs in psoriasis
In healthy skin and blood, ILC2 and
ILC3s are present at low levels and
express the cutaneous lymphocyte-
associated antigen (CLA), thus having
the capacity to localize in skin. Although
few ILC3s are found in normal healthy
skin, when grown ex vivo as cultured
dermal explants, they express IL-22. Of
particular translational importance were
the findings by both Teunissen et al.
(2014) and Villanova et al. (2014)
showing increases in the ILC3 (and
not the ILC1 or ILC2) population in
involved- and uninvolved-psoriasis skin
and in peripheral blood that produced
IL-22 and possibly IL-17A, two cyto-
kines known to be especially patho-
genic in human psoriasis. Moreover,
ILC3s cultured ex vivo responded to
IL-1b and IL-23, cytokines known to be
elevated in psoriasis, and this converted
them to the activated natural cytotoxi-
city receptor positive (NCRþ ) form of
ILC3 that produces IL-22. Although
Teunissen et al. (2014) did not directly
demonstrate ILC3-derived IL-17A in
human psoriasis skin, Villanova et al.
(2014) reported the ability of ILC3s in
psoriasis skin and blood to produce both
IL-17A and IL-22. These results may
reflect methodological differences in
how cells were isolated, the purity of
the cell populations, and/or differences
among the patients from whom the cells
were taken. Interestingly, work per-
formed in our laboratories using fresh
psoriasis patient skin, both involved and
uninvolved, has validated the increased
presence (B4-fold) of IL-22-producing
ILC3s (S Yu, data not shown). However,
we have not yet examined whether
these cells produce IL-17A. All of these
observations, taken together, suggest
that ILC3s serve as innate counterparts
to skin-resident memory T cells, are a
significant source of pathogenic cyto-
kines in psoriatic skin, and perhaps
serve as a first line of defense in the
skin, one that initiates the development
of psoriasis.
Another observation specifically rele-
vant to psoriasis may be found in a
recent report by one of the same groups
(Hergen Spits and Jenny Mjosberg)
who identified tonsil-resident ILC3s that
also respond to IL-1b and IL-23 with
the production of IL-22 and IL-17A
(Bernink et al., 2013). Considering
recent evidence that psoriasis patients’
tonsils have a higher frequency of skin-
homing lymphocytes (Sigurdardottir
et al., 2013) and that psoriasis patients
often report onset or worsening of their
skin disease after Streptococcal infection
(Gudjonsson et al., 2003), it will be
interesting to determine whether tonsil-
resident ILC3s in psoriasis patients
upregulate CLA following Streptococcal
infection. Such a relationship would
support a role for ILC3s in psoriasis
initiation and pathogenesis.
Both Teunissen et al. (2014) and
Villanova et al. (2014) demonstrated a
correlation between ILC3 frequency and
severity of psoriasis, as measured by
using the psoriasis area severity index
(PASI) scoring system, and Villanova
et al. (2014) have also demonstrated a
75% decrease in ILC3s following TNFa
inhibition (using adalimumab) in one
patient. These results extend the work
of Powell et al. (2012), showing
that IL-23 and TNFa can drive ILC3
differentiation, and of Zaba et al.
(2009), demonstrating that IL-17/TNFa
signature transcriptome probe sets
predict disease remission in patients
treated with etanercept (soluble TNFa
receptor). Thus, it is likely that ILC3s
and their elaborated cytokines are
suppressed following TNFa inhibition
in patients who are responsive to TNFa
inhibition. Similarly, it is likely that
IL-12/23 inhibitors also target ILC3s,
based upon the capacity of IL-23 to
drive differentiation and secretion of
IL-17A/IL-22 from ILC3s.
While IL-17/IL-23 inhibitors are show-
ing considerable efficacy in clinical
trials for psoriasis, IL-22 inhibitors have
thus far failed clinically for psoriasis.
IL-22 appears to have a critical role in
driving keratinocyte hyperproliferation,
a major feature of psoriasis. However,
targeting it directly may be insufficient.
Targeting IL-23 or IL-17 (produced by
T cells (ab and gd), neutrophils, and
ILC3s) inhibits IL-17A directly, and it
also likely targets T-cell– and ILC3-
derived IL-22. It is possible that the
combined targeting of both IL-17A and
IL-22 leads to a better clinical resolu-
tion. Future work exploring relative cell-
specific contributions to IL-17-mediated
inflammatory responses may provide
additional insights into key cellular
players in psoriasis pathogenesis.
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Gene Regulation at a Distance:
Higher-Order Chromatin Folding and
the Coordinated Control of Gene
Transcription at the Epidermal
Differentiation Complex Locus
Michael Y. Fessing1
Chromatin structure and spatial interactions between proximal and distal gene
regulatory elements, including gene core promoters and enhancers, are important
in the control of gene transcription. In this issue, Oh et al. characterized an AP-1-
dependent enhancer at the epidermal differentiation complex locus that estab-
lishes spatial interactions with numerous gene promoter regions at that locus.
Journal of Investigative Dermatology (2014) 134, 2307–2310. doi:10.1038/jid.2014.247
All somatic cells in a multicellular
organism share identical DNA content,
but demonstrate vastly different pheno-
types, as is required for tissue and organ
development and homeostasis. Such
differences are based on tissue-specific
programs of gene expression established
in multi-potent progenitor cells and their
differentiating progenies. In mammals,
gene expression programs are controlled
at multiple levels, including gene trans-
cription. Transcription of protein-coding
and the majority of protein noncoding
genes is regulated by binding of and
interactions between numerous regula-
tory proteins, RNA polymerase II, and
proximal and distal gene cis-regulatory
elements. The best studied type of func-
tional interaction between cis-regulatory
elements is spatial contact between
the gene core promoter and enhancer
regions, which may be separated by
hundreds of kilobase pairs, or they could
even be located on different chromo-
somes (Bulger and Groudine, 2011;
Harmston and Lenhard, 2013). Because
DNA is organized in a nuclear–protein
complex called chromatin, chromatin
structural remodeling is required to con-
trol protein binding to the regulatory
regions and to establish contact between
the distal and proximal gene regulatory
elements (Rando and Chang, 2009).
Proper higher-order chromatin folding
in the three-dimensional (3D) nuclear
space is important in establishing func-
tional interactions between the promo-
ters and enhancers involved in controll-
ing cell-type–specific gene transcription
for numerous genes, including Shh, as
well as the genes that constitute the
b-globin, a-globin, and Hox gene loci
(Bulger and Groudine, 2011; Gibcus
and Dekker, 2013). Genome-wide asso-
ciation studies have demonstrated that
many single-nucleotide polymorphisms
identified in the intergenic regions are
associated with human diseases, sug-
gesting that such defects might perturb
normal gene expression programs by
affecting distal gene cis-regulatory ele-
ments (Maurano et al., 2012).
Functionally related and coregulated
genes often form multi-gene loci in
mammalian genomes. Genes involved
in execution of keratinocyte-specific
gene expression programs are clustered
in at least three evolutionally conserved
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